Detrusor overactivity—an update
Article first published online: 1 DEC 2004
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 111, Issue Supplement s1, pages 53–56, December 2004
How to Cite
Toozs-Hobson, P. and Elnaqa, A. (2004), Detrusor overactivity—an update. BJOG: An International Journal of Obstetrics & Gynaecology, 111: 53–56. doi: 10.1111/j.1471-0528.2004.00468.x
- Issue published online: 1 DEC 2004
- Article first published online: 1 DEC 2004
- 4and the oxybutynin CR Study Group. Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared to conventional treatment. Neurourol Urodyn 1997;16:429–430., ,
- 5The efficacy, effectiveness, and safety of transdermal oxybutynin in patients with overactive bladder. Neurourol Urodyn 2003;22:533–534., , , et al.
- 7Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997;16:478–479., , .
- 10Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder. Neurourol Urodyn 2003;22:534–535., , , , , .
- 13Nonsurgical management of incontinence. In: MacleanAB, CardozoLD, editors. Incontinence in Women. RCOG Press, 2002 Chapter 16..
- 14Anti-diuresis—for the control of daytime incontinence. Int Urogynecol J 2002;13:S6., , , , , .